Art

J-GLOBAL ID：201702239986893461   Reference number：17A1802363

Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study

再発性あるいは難治性末梢性T細胞リンパ腫を持つ日本人患者におけるロミデプシン:第I/II相および薬物動態試験

Author (23)： MARUYAMA Dai (National Cancer Center Hospital, Tokyo, JPN) ,  TOBINAI Kensei (National Cancer Center Hospital, Tokyo, JPN) ,  OGURA Michinori (Tokai Central Hospital, Gifu, JPN) ,  OGURA Michinori (Nagoya Daini Red Cross Hospital, Aichi, JPN) ,  UCHIDA Toshiki (Nagoya Daini Red Cross Hospital, Aichi, JPN) ,  HATAKE Kiyohiko (Cancer Inst. Hospital of Japanese Foundation for Cancer Res., Tokyo, JPN) ,  TANIWAKI Masafumi (Kyoto Prefectural Univ. Medicine, Kyoto, JPN) ,  ANDO Kiyoshi (Tokai Univ. School of Medicine, Kanagawa, JPN) ,  TSUKASAKI Kunihiro (National Cancer Center Hospital East, Chiba, JPN) ,  ISHIDA Takashi (Nagoya City Univ. Graduate School of Medical Sci., Aichi, JPN) ,  KOBAYASHI Naoki (Sapporo Hokuyu Hospital, Hokkaido, JPN) ,  ISHIZAWA Kenichi (Tohoku Univ. Hospital, Miyagi, JPN) ,  ISHIZAWA Kenichi (Yamagata Univ. Fac. of Medicine, Yamagata, JPN) ,  TATSUMI Yoichi (Kinki Univ. Hospital, Fac. of Medicine, Osaka, JPN) ,  KATO Koji (Kyushu Univ. Hospital, Fukuoka, JPN) ,  KIGUCHI Toru (Chugoku Central Hospital, Hiroshima, JPN) ,  IKEZOE Takayuki (Kochi Medical School Hospital, Kochi, JPN) ,  IKEZOE Takayuki (Fukushima Medical Univ. School of Medicine, Fukushima, JPN) ,  LAILLE Eric (Celgene Corp., NJ, USA) ,  RO Tokihiro (Celgene K.K., Tokyo, JPN) ,  TAMAKOSHI Hiromi (Celgene K.K., Tokyo, JPN) ,  SAKURAI Sanae (Celgene K.K., Tokyo, JPN) ,  OHTSU Tomoko (Celgene K.K., Tokyo, JPN)
Material： International Journal of Hematology  (Int J Hematol)
Volume： 106  Issue： 5  Page： 655-665  Publication year： Nov. 2017 
JST Material Number： F0888A  ISSN： 0925-5710  CODEN： IJHEEY  Document type： Article
Article type： 原著論文  Country of issue： Germany, Federal Republic of (DEU)  Language： ENGLISH (EN)

Thesaurus term： human ,...
Semi thesaurus term： *Peripheral T cell lymphoma

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=17A1802363&from=J-GLOBAL&jstjournalNo=F0888A") }}

JST classification (1)： Clinical application of antitumor(=antineoplastic)drugs  (GW16020L)

Substance index (1)： Romidepsin

Reference (40)：

• Karlin L, Coiffier B. The changing landscape of peripheral T-cell lymphoma in the era of novel therapies. Semin Hematol. 2014;51:25-34.
• Vose J, Armitage J, Weisenburger D, International TCLP. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124-30.
• Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA, et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood. 2011;117:3402-8.
• Mak V, Hamm J, Chhanabhai M, Shenkier T, Klasa R, Sehn LH, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013;31:1970-6.
• SEER Cancer Statistics Factsheets: Non-Hodgkin Lymphoma. National Cancer Institute. Bethesda, MD. https://seer.cancer.gov/statfacts/html/nhl.html. Accessed 17 Jan 2017.

Terms in the title (6)： 再発 ,  末梢性T細胞リンパ腫 ,  日本人 ,  患者 ,  ロミデプシン ,  薬物動態試験